Making an ‘off-the-shelf’ CAR-T cell treatment for children with solid cancers
Creating an immunotherapy that can be delivered to patients more quickly and cost-effectively.
Understanding how a new drug can selectively fight childhood cancer cells
Testing a new type of targeted treatment that applies to multiple types of childhood cancers.
Rewriting cancer cell messages to slow down tumour growth
Testing medicines that can correct the genetic messages that help cancer cells grow out of control.
How do immune cells protect childhood ependymoma tumours?
Looking at how brain tumours hijack immune cells, forcing them to support cancer growth instead of fighting it.
Investigating the shape of fusion genes in rhabdomyosarcoma
How the 3D shape of fusion gene genetic code affects cancer cell behaviour and whether shape-modifying medicines could mitigate these effects.
Predicting high-risk rhabdomyosarcoma at diagnosis to improve outcomes
Assessing rhabdomyosarcoma risk prediction markers based on the biological conditions in the tumour, like low oxygen levels, few blood vessels, and genetics.
Determining the best approach to treat children with relapsed anaplastic large cell lymphoma
Looking at why ALCL sometimes relapses with a new targeted treatment, and understanding how to optimise this treatment approach.
Getting the ending right - feeling prepared to move into survivorship care when active treatment finishes
Understanding what information patients and families want, at what points in their cancer journey.
Creating the West Midlands Childhood Cancer Clinical Cohort
Gathering data to uncover how childhood cancer and its treatment impacts survivors long-term quality of life.